Matthew Brams - 06 Feb 2026 Form 4 Insider Report for Cingulate Inc. (CING)

Role: EVP and Chief Medical Officer
Signature: /s/ Shane J. Schaffer, Attorney-in-Fact
Issuer symbol: CING
Transactions as of: 06 Feb 2026
Net transactions value: +$9,963
Form type: 4
Filing time: 10 Feb 2026, 19:00:19 UTC
Previous filing: 09 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Brams Matthew	EVP and Chief Medical Officer	1901 W. 47TH PLACE, KANSAS CITY	/s/ Shane J. Schaffer, Attorney-in-Fact	10 Feb 2026	0001884361

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CING	Common Stock	Purchase	$9,808	+1,946	+72%	$5.04	4,656	06 Feb 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CING	Warrant to Purchase Common Stock	Purchase	$156	+1,556		$0.1000	1,556	06 Feb 2026	Common Stock	1,556	$5.04	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026.
F2	The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date.